NovoCure Limited kicked off the trading day on 10/10/19 with a price increase of 4.10%, equivalent to $2.97 relative change for the day. Taking a more long-term approach, NVCR had a 52-week range of $26.02 to $98.70. At the time of this article’s publishing, this stock is trading at $75.49 after starting the trading session at $72.28. At the time of writing, this stock’s 50-day Moving Average stands at $83.28, while the 200-day Moving Average of this stock is currently $59.85.
Currently, this company’s share volume is sitting at $1133962, but has maintained average daily volume of $854.64K. This stock has generated an average Year to Date volume of $734674, alongside an average 20-day volume of $669830. This publicly-traded company’s shares outstanding now amounts to $96.07 million, simultaneously with a float of $80.66 million. The organization now has a market capitalization sitting at $7.25 billion.
NovoCure Limited(NVCR) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. NovoCure Limited’s current insider ownership accounts for 1.70%, in contrast to 74.90% institutional ownership. According to the most recent latest insider trade that took place on Sep 24 this organization’s CFO exercised an option 7,992 at the rate of 4.32, making the entire transaction hit 34,532 in total value, affecting insider ownership by 91,210. Preceding that transaction, on Sep 24 Company’s CFO sold 7,992 at a price of 80.63, making the whole transaction’s value amount to 644,398. This particular insider is now the holder of 87,179 in total.
If we take a glance at the Ownership summary of NovoCure Limited’s stock, Institutional holders make up 74.90% of its total stock ownership. All together, they are the legal holders of 96.07M shares. If we focus on the top 3 stockholders for this publicly-traded organization, Fidelity Management & Research Co. owns 10,288,668 shares, with Baillie Gifford & Co. in 2nd place owning 8,829,449 shares and The Vanguard Group, Inc. in third place with total ownership of 5,985,535 shares.
NovoCure Limited (NVCR) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 6/29/2019, the organization reported -$0.01 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$0.07) by $0.06.
This company achieved a net margin of -13.84 while generating a return on equity of -32.62. NovoCure Limited’s full-quarter revenue increased by 40.83%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
NovoCure Limited’s EPS increase for this current 12-month fiscal period is 36.50%, and is forecasted to reach 0.40 in the upcoming year.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for NovoCure Limited, this organization’s Quick Ratio in the last reported quarter now stands at 4.70. The company has managed to achieve an average true range (ATR) of 3.35. Alongside those, its Beta score is 2.34.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 24.63 for this organization. Similarly, its price to free cash flow for trailing twelve months is now 300.93. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 45.75, whereas its price to cash per share for the last quarter landed at 2.96.
In the same vein, NVCR’s Diluted EPS (Earnings per Share) trailing twelve months was posted at -0.44, a figure that is expected to reach -0.05 in the next reported quarter, and analysts expect it will be 0.40 at the market close of one year from today’s date.